Gilead Sciences, Inc. $GILD Stock Holdings Raised by Royal Fund Management LLC

Royal Fund Management LLC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 827.4% in the 3rd quarter, HoldingsChannel reports. The firm owned 23,861 shares of the biopharmaceutical company’s stock after acquiring an additional 21,288 shares during the quarter. Royal Fund Management LLC’s holdings in Gilead Sciences were worth $3,557,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GILD. NBT Bank N.A. acquired a new position in shares of Gilead Sciences during the third quarter valued at about $1,155,000. Root Financial Partners LLC boosted its position in shares of Gilead Sciences by 28.9% during the 3rd quarter. Root Financial Partners LLC now owns 2,441 shares of the biopharmaceutical company’s stock worth $364,000 after purchasing an additional 548 shares in the last quarter. Lmcg Investments LLC boosted its position in shares of Gilead Sciences by 0.5% during the 3rd quarter. Lmcg Investments LLC now owns 17,602 shares of the biopharmaceutical company’s stock worth $2,624,000 after purchasing an additional 90 shares in the last quarter. Vest Financial LLC grew its stake in shares of Gilead Sciences by 0.4% in the 3rd quarter. Vest Financial LLC now owns 24,851 shares of the biopharmaceutical company’s stock valued at $3,704,000 after buying an additional 111 shares during the period. Finally, PFS Partners LLC grew its stake in shares of Gilead Sciences by 101.1% in the 3rd quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 96 shares during the period. 83.67% of the stock is owned by institutional investors.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Earnings expectations are supportive. Analysts expect Gilead to potentially beat its upcoming third-quarter estimates, supported by favorable estimate revisions and the company’s history of exceeding consensus forecasts. A strong report or upbeat outlook could reinforce the recent momentum. Gilead Sciences Expected to Beat Earnings Estimates
• Positive Sentiment: Oncology pipeline receives a potential boost. Gilead and BioNTech entered a clinical-trial collaboration and supply agreement to test BioNTech’s pumitamig with Gilead’s TROP2-directed antibody-drug conjugate sacituzumab govitecan in the Phase 3 ROSETTA Breast-01 trial for advanced triple-negative breast cancer. Success could expand the commercial opportunity for Trodelvy and support Gilead’s strategy of building growth beyond HIV. BioNTech and Gilead to Test Drug Combination
• Positive Sentiment: Investors are highlighting longer-term growth drivers. A bullish investment thesis points to Gilead’s durable HIV franchise, oncology expansion and potential for pipeline-led growth without relying primarily on acquisitions. Bank of America also reportedly expects additional upside, adding to the positive analyst narrative. Bank of America Analyst Expects Gilead Stock to Rise
• Neutral Sentiment: Upcoming liver-disease data could provide another catalyst. Gilead plans to present clinical and real-world evidence on primary biliary cholangitis and chronic hepatitis delta at The Liver Meeting in November. The data may support confidence in long-term treatment durability and disease management, although the investment impact will depend on the results. Gilead to Present New Liver-Disease Data
• Negative Sentiment: Valuation and clinical execution remain risks. The shares recently declined during one session despite broader market gains, indicating some sensitivity to profit-taking or company-specific concerns. The BioNTech program is still dependent on Phase 3 results, while the stock’s proximity to its high leaves less room for disappointment if earnings or pipeline data fall short. Gilead Stock Drops Despite Market Gains

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Weiss Ratings upgraded Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. Needham & Company LLC reiterated a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a report on Wednesday, August 5th. Jefferies Financial Group reissued a “buy” rating on shares of Gilead Sciences in a research note on Friday. Finally, Bank of America boosted their price objective on Gilead Sciences from $168.00 to $172.00 and gave the company a “buy” rating in a report on Tuesday. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $159.63.

Insider Activity

In other news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $137.64, for a total value of $3,853,920.00. Following the transaction, the insider owned 118,234 shares in the company, valued at $16,273,727.76. The trade was a 19.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the transaction, the chief financial officer directly owned 161,096 shares in the company, valued at approximately $25,166,417.12. This represents a 1.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 111,000 shares of company stock worth $15,877,860. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Trading Up 2.4%

GILD opened at $157.19 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. Gilead Sciences, Inc. has a fifty-two week low of $114.02 and a fifty-two week high of $160.51. The firm has a market capitalization of $194.91 billion, a PE ratio of -58.87 and a beta of 0.31. The company’s 50-day moving average is $148.74 and its 200 day moving average is $137.72.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping the consensus estimate of ($7.25) by $0.50. The firm had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The company’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the business posted $2.01 earnings per share. As a group, research analysts predict that Gilead Sciences, Inc. will post -0.47 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th were given a dividend of $0.82 per share. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.1%. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.